Intervention

LCZ696

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 32 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials32

Recruiting0

Common conditions19

Lead sponsors shown3

Clinical trials

32 shown

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.NCT03909295 · 2019-05-07

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart FailureNCT03917459 · 2019-04-16

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1NCT03738878 · 2018-11-15

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)NCT02816736 · 2017-03-02

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection FractionNCT02884206 · 2016-11-23

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart FailureNCT02678312 · 2016-11-03

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.NCT02768298 · 2016-07-12

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation EventNCT02661217 · 2016-02-12

Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection FractionNCT02468232 · 2015-06-15

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionNCT02226120 · 2014-10-16

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionNCT01920711 · 2014-07-18

Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With HypertensionNCT01865188 · 2014-04-01

Safety and Tolerability of Initiating LCZ696 in Heart Failure PatientsNCT01922089 · 2013-11-01

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to OlmesartanNCT01876368 · 2013-09-01

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential HypertensionNCT01785472 · 2013-04-01

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With HypertensionNCT01692301 · 2012-12-01

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive SubjectsNCT01631864 · 2012-10-01

Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate HypertensionNCT01601470 · 2012-09-01

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive HypertensionNCT01681576 · 2012-08-01

Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to AmlodipineNCT01663233 · 2012-08-01

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential HypertensionNCT01615198 · 2012-08-01

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive PatientsNCT01646671 · 2012-07-01

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential HypertensionNCT01599104 · 2012-06-01

Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal DysfunctionNCT01593787 · 2012-05-01

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy VolunteersNCT01353508 · 2011-03-01

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic HypertensionNCT01281306 · 2011-01-01

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential HypertensionNCT01256411 · 2010-11-01

Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential HypertensionNCT01193101 · 2010-08-01

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection FractionNCT00887588 · 2009-11-01

Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart FailureNCT00913653 · 2009-05-01

Efficacy and Safety of LCZ696A in Patients With Essential HypertensionNCT00549770 · 2007-09-01

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)NCT02389933

NO_LONGER_AVAILABLE

Common conditions

Hypertension8 Essential Hypertension5 Heart Failure3 Chronic Heart Failure With Reduced Ejection Fraction2 Heart Failure With Reduced Ejection Fraction2 Heart Failure With Reduced Ejection Fraction (HF-rEF)2 Chronic Heart Failure1 Chronic Heart Failure (CHF)1 Concurrent Obesity1 Erectile Dysfunction1 Heart Failure With Preserved Ejection Fraction1 Heart Failure With Preserved Ejection Fraction (HFpEF)1 Heart Failure, Systolic1 Hypertension With Renal Dysfunction1 Mild to Moderate Hypertension1 Pediatric Heart Failure1 Salt-sensitive Hypertension1 Severe Hypertension1 Systolic Hypertension1

Leading sponsors

Novartis Pharmaceuticals 30 Duke University 1 Vanderbilt University Medical Center 1

Trial status mix

COMPLETED28

TERMINATED2

NO_LONGER_AVAILABLE1

WITHDRAWN1

Phase mix

PHASE315

PHASE213

PHASE44

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.